Juniper Pharmaceuticals, Inc. (JNP)
Seite 1 von 1 Neuester Beitrag: 25.04.21 00:11 | ||||
Eröffnet am: | 21.05.17 11:57 | von: Chalifmann3 | Anzahl Beiträge: | 7 |
Neuester Beitrag: | 25.04.21 00:11 | von: Karolinpdnia | Leser gesamt: | 4.070 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
hm ?
A number of other large investors have also recently added to or reduced their stakes in JNP. Stonepine Capital Management LLC increased its stake in Juniper Pharmaceuticals by 31.3% in the fourth quarter. Stonepine Capital Management LLC now owns 228,392 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after buying an additional 54,425 shares during the period. Eagle Global Advisors LLC increased its stake in Juniper Pharmaceuticals by 29.3% in the third quarter. Eagle Global Advisors LLC now owns 44,442 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 10,070 shares during the period. Spark Investment Management LLC increased its stake in Juniper Pharmaceuticals by 11.3% in the third quarter. Spark Investment Management LLC now owns 48,400 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 4,900 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Juniper Pharmaceuticals by 26.3% in the third quarter. Wells Fargo & Company MN now owns 145,586 shares of the specialty pharmaceutical company’s stock worth $808,000 after buying an additional 30,286 shares during the period. Hedge funds and other institutional investors own 33.12% of the company’s stock.
A number of analysts have recently weighed in on JNP shares. Roth Capital set a $12.00 target price on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, May 6th. HC Wainwright reaffirmed a “hold” rating on shares of Juniper Pharmaceuticals in a research report on Friday, May 5th. Finally, TheStreet upgraded shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Wednesday, April 12th.
A number of institutional investors have recently bought and sold shares of JNP. Goldman Sachs Group Inc. bought a new position in Juniper Pharmaceuticals during the first quarter valued at about $100,000. KCG Holdings Inc. bought a new position in Juniper Pharmaceuticals during the first quarter valued at about $112,000. TFS Capital LLC boosted its position in Juniper Pharmaceuticals by 87.0% in the first quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 14,707 shares in the last quarter. Acadian Asset Management LLC boosted its position in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares in the last quarter. Finally, Eagle Global Advisors LLC boosted its position in Juniper Pharmaceuticals by 29.3% in the third quarter. Eagle Global Advisors LLC now owns 44,442 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 10,070 shares in the last quarter. Institutional investors and hedge funds own 33.12% of the company’s stock.
Juniper Pharmaceuticals (NASDAQ:JNP) remained flat at $4.15 during trading on Tuesday. The stock had a trading volume of 17,799 shares. Juniper Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $8.00. The firm’s 50 day moving average is $4.22 and its 200 day moving average is $4.94. The company has a market capitalization of $45.00 million, a P/E ratio of 7.35 and a beta of 0.25.
Juniper Pharmaceuticals (NASDAQ:JNP) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.04. The business had revenue of $11.25 million during the quarter, compared to analysts’ expectations of $11.27 million. Juniper Pharmaceuticals had a negative return on equity of 9.68% and a negative net margin of 7.44%. Equities analysts forecast that Juniper Pharmaceuticals will post ($0.45) earnings per share for the current year.
Analysts Set Juniper Pharmaceuticals, Inc. (JNP) Price Target at $12.00
June 21st, 2017 - By Scott Moore - 0 comments
Juniper Pharmaceuticals logoShares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have earned a consensus rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.00.
A number of analysts have recently issued reports on JNP shares. TheStreet raised shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a report on Wednesday, April 12th. HC Wainwright reiterated a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Friday, May 5th. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 6th. Finally, ValuEngine cut shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd.